GenMark Diagnostics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. GenMark is a Delaware corporation and, in connection with the offering, will become the parent holding company of Osmetech, plc.
Piper Jaffray & Co. will act as the sole book-running manager, and Leerink Swann LLC will act as the co-manager for the proposed offering. The number of shares to be offered and the price range of the proposed offering have not yet been determined. All of the shares of common stock will be offered by GenMark.
The proposed offering will be made only by means of a prospectus. Once available, a preliminary prospectus relating to the proposed offering may be obtained from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling (800) 747-3924.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The prospectus related to the proposed offering will be included in the registration statement.
COVID-19's lasting impact on smell and brain health unveiled